blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2406283

EP2406283 - ANTIBODY MOLECULES HAVING BINDING SPECIFICITY FOR HUMAN IL-13 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.09.2017
Database last updated on 12.11.2024
Most recent event   Tooltip06.10.2017Lapse of the patent in a contracting state
???moredetails.lapse.edited??? SM		published on 08.11.2017  [2017/45]
Applicant(s)For all designated states
UCB Biopharma SPRL
Allée de la Recherche 60
1070 Brussels / BE
[2015/30]
Former [2012/03]For all designated states
UCB Pharma, S.A.
60, allée de la Recherche
1170 Brussels / BE
Inventor(s)01 / GOZZARD, Neil
Ipd
Ucb Celltech
208 Bath Road
Slough Berkshire SL1 3WE / GB
02 / LAWSON, Alastair, David, Griffiths
Ipd
Ucb Celltech
208 Bath Road
Slough Berkshire SL1 3WE / GB
03 / LIGHTWOOD, Daniel, John
Ipd
Ucb Celltech
208 Bath Road
Slough Berkshire SL1 3WE / GB
04 / PALFRAMAN, Roger, Thomas
Ipd
Ucb Celltech
208 Bath Road
Slough Berkshire SL1 3WE / GB
05 / SMITH, Bryan, John
Ipd
Ucb Celltech
208 Bath Road
Slough Berkshire SL1 3WE / GB
06 / TYSON, Kerry, Louise
Ipd
Ucb Celltech
208 Bath Road
Slough Berkshire SL1 3WE / GB
 [2012/03]
Representative(s)Blanchard, Amanda Jane
UCB Celltech
208 Bath Road
Slough, Berkshire SL1 3WE / GB
[2016/46]
Former [2012/03]Blanchard, Amanda Jane
UCB Celltech 208 Bath Road
Slough, Berkshire SL1 3WE / GB
Application number, filing date10714046.910.03.2010
[2016/46]
WO2010GB00432
Priority number, dateGB2009000421411.03.2009         Original published format: GB 0904214
[2012/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010103274
Date:16.09.2010
Language:EN
[2010/37]
Type: A1 Application with search report 
No.:EP2406283
Date:18.01.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 16.09.2010 takes the place of the publication of the European patent application.
[2012/03]
Type: B1 Patent specification 
No.:EP2406283
Date:16.11.2016
Language:EN
[2016/46]
Search report(s)International search report - published on:EP16.09.2010
ClassificationIPC:C07K16/24, A61K39/395, A61P11/06, C07K16/46, C12N15/13
[2012/03]
CPC:
C07K16/244 (EP,EA,US); A61K39/3955 (EA,US); A61K9/0078 (EA,US);
A61P11/00 (EP); A61P11/06 (EP); A61P29/00 (EP);
A61P31/12 (EP); A61P35/00 (EP); A61P37/00 (EP);
A61P37/02 (EP); A61P37/08 (EP); A61P43/00 (EP);
A61P9/00 (EP); A61K2039/505 (EP,EA,US); A61K2039/544 (EP,EA,US);
A61K39/395 (EA,US); C07K2317/24 (EP,EA,US); C07K2317/33 (EP,EA,US);
C07K2317/51 (EA,US); C07K2317/515 (EA,US); C07K2317/55 (EP,EA,US);
C07K2317/56 (EP,EA,US); C07K2317/565 (EP,EA,US); C07K2317/76 (EP,EA,US);
C07K2317/92 (EP,EA,US); C07K2317/94 (EP,EA,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/03]
Extension statesAL11.10.2011
BA11.10.2011
ME11.10.2011
RS11.10.2011
TitleGerman:ANTIKÖRPERMOLEKÜLE MIT BINDUNGSSPEZIFITÄT FÜR HUMANES IL-13[2012/03]
English:ANTIBODY MOLECULES HAVING BINDING SPECIFICITY FOR HUMAN IL-13[2012/03]
French:MOLÉCULES D'ANTICORPS AYANT UNE SPÉCIFICITÉ DE LIAISON POUR IL-13 HUMAIN[2012/03]
Entry into regional phase11.10.2011National basic fee paid 
11.10.2011Designation fee(s) paid 
11.10.2011Examination fee paid 
Examination procedure11.10.2011Examination requested  [2012/03]
30.04.2012Amendment by applicant (claims and/or description)
04.03.2015Despatch of a communication from the examining division (Time limit: M06)
11.09.2015Reply to a communication from the examining division
01.10.2015Despatch of a communication from the examining division (Time limit: M02)
13.11.2015Reply to a communication from the examining division
08.06.2016Communication of intention to grant the patent
07.10.2016Fee for grant paid
07.10.2016Fee for publishing/printing paid
07.10.2016Receipt of the translation of the claim(s)
Divisional application(s)EP16198084.2  / EP3168235
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.03.2015
Opposition(s)17.08.2017No opposition filed within time limit [2017/43]
Fees paidRenewal fee
31.03.2012Renewal fee patent year 03
02.04.2013Renewal fee patent year 04
31.03.2014Renewal fee patent year 05
31.03.2015Renewal fee patent year 06
31.03.2016Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipSM16.11.2016
[2017/45]
Former [2017/13]deleted
Former [2017/12]LV16.11.2016
Cited inInternational search[Y]US2004115194  (WANG YI [US]) [Y] 26-28 * figures 5,7; example 3 *;
 [I]GB2403952  (CAMBRIDGE ANTIBODY TECH [GB]) [I] 1-10,12,14-18,22-28 * examples 1,11-12 *;
 [Y]US2005271660  (WANG YI [US]) [Y] 26-28* example - *;
 [I]US2006063228  (KASAIAN MARION T [US], et al) [I] 1-10,12,14-18,22-28 * examples 1,3 *;
 [XYI]WO2006055638  (ABGENIX INC [US], et al) [X] 16-18,22,24,25,28 * paragraphs [0121] , [0186] , [0292] , [0235]; examples 1-4,18; table 9 * [Y] 26-28 [I] 1-15,19-21,23,26,27;
 [Y]US2008075720  (HOLERS VERNON M [US], et al) [Y] 26-28 * examples 1-2 *;
 [XI]WO2008086395  (WYETH CORP [US], et al) [X] 14,22-25,28 * page 7, line 22 - page 9, line 19; figure 34; examples 4,12,15; claims 1,35,41-43 * * page 2, line 2 - page 4, line 8 * [I] 1-10,12,15-18,26,27
by applicant   - ZURAWSKI; VRIES, IMMUNOL TODAY, (1994), vol. 15, pages 19 - 26
    - ZURAWSKI; VRIES, IMMUNOL LODAY, (1994), vol. 13, pages 19 - 26
    - PUNNONEN; AVERSA ET AL., PROC NATL ACAD SCI USA, (1993), vol. 90, pages 3730 - 4
    - WAAL MALEFYT; FIGDOR ET AL., J IMMUNOL, (1993), vol. 151, pages 6370 - 81
    - DOHERTY; KASTELEIN ET AL., J IMMUNOL, (1993), vol. 151, pages 7151 - 60
    - AMAN; TAYEBI ET AL., J BIOL CHEM, (1996), vol. 271, pages 29265 - 70
    - HILTON; ZHANG ET AL., PROC NATL ACAD SCI U S A, (1996), vol. 93, pages 497 - 501
    - GRABER; GRETENER ET AL., EUR J IMMUNOL, (1998), vol. 28, pages 4286 - 98
    - MURATA; HUSAIN ET AL., INT IMMUNOL, (1998), vol. 10, pages 1103 - 10
    - AKAIWA, YU ET AL., CYTOKINE, (2001), vol. 13, pages 75 - 84
    - WANG; MICHIELI ET AL., BLOOD, (1995), vol. 864218, page 27
    - TAKEDA; KAMANAKA ET AL., J IMMUNOL, (1996), vol. 157, pages 3220 - 2
    - DONALDSON; WHITTERS ET AL., J IMMUNOL, (1998), vol. 161, pages 2317 - 24
    - FICHTNER-FEIGL; STROBER ET AL., NAT MED, (2006), vol. 12, pages 99 - 106
    - SEIA, HAREFUAH, (1999), vol. 137, pages 317 - 9
    - WILLS- KARP; CHIARAMONTE, CURR OPIN PUIM MED, (2003), vol. 9, pages 21 - 7
    - WILLS-KARP, IMMUNOL REV, (2004), vol. 202, pages 175 - 90
    - GRUNIG; WARNOCK ET AL., SCIENCE, (1998), vol. 282, pages 2261 - 3
    - WILLS-KARP; LUYIMBAZI ET AL., SCIENCE, (1998), vol. 282, pages 2258 - 61
    - KIBE; INOUE ET AL., AM J RESPIR CRIT CARE MED, (2003), vol. 167, pages 50 - 6
    - VARGAFTIG; SINGER, AM J PHYSIOL LUNG CELL MOL PHYSIOL, (2003), vol. 284, pages L260 - 9
    - VARGAFTIG; SINGER, AM J RESPIR CELL MOL BIOL, (2003), vol. 28, pages 410 - 9
    - ZHU; HOMER ET AL., J CLIN INVEST, (1999), vol. 103, pages 779 - 88
    - ZHU; LEE ET AL., AM J RESPIR CRIT CARE MED, (2001), vol. 164, pages 67 - 70
    - KUPERMAN; HUANG ET AL., NAT MED, (2002), vol. 8, pages 885 - 9
    - TAUBE; DUEZ ET AL., J IMMUNOL, (2002), vol. 169, pages 6482 - 9
    - HUANG; XIAO ET AL., J IMMUNOL, (1995), vol. 155, pages 2688 - 94
    - HEINZMANN; MAO ET AL., HUM MOI GENET, (2000), vol. 9, pages 549 - 59
    - HOERAUF, KRUSE ET AL., MICROBES INFECT, (2002), vol. 4, pages 37 - 42
    - VERCELLI, CURR OPIN ALLERGY CLIN IMMUNOL, (2002), vol. 2, pages 389 - 93
    - HEINZMANN; JERKIC ET AL., J ALLERGY CLIN IMMUNOL, (2003), vol. 112, pages 735 - 9
    - CHEN; ERICKSEN ET AL., J ALLERGY CLIN IMMUNOL, (2004), vol. 114, pages 553 - 60
    - HUANG, XIAO ET AL., J IMMUNOL, (1995), vol. 155, pages 2688 - 94
    - ARIMA; UMESHITA-SUYAMA ET AL., J ALLERGY CLIN IMMUNOL, (2002), vol. 109, pages 980 - 7
    - BERRY; PARKER ET AL., J ALLERGY CLIN IMMUNOL, (2004), vol. 114, pages 1106 - 9
    - WILLS-KARP, RESPIR RES, (2000), vol. 1, pages 19 - 23
    - CHOTHIA, C.; LESK, A.M., J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, pages 495 - 497
    - KOZBOR ET AL., IMMUNOLOGY TODAY, (1983), vol. 4, page 72
    - BABCOOK, J. ET AL., PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, no. 15, pages 7843 - 78481
    - KASHMIRI ET AL., METHODS, (2005), vol. 36, pages 25 - 34
    - BRINKMAN ET AL., J. IMMUNOL. METHODS, (1995), vol. 182, pages 41 - 50
    - AMES ET AL., J. IMMUNOL. METHODS, (1995), vol. 184, pages 177 - 186
    - KETTLEBOROUGH ET AL., EUR. J. IMMUNOL., (1994), vol. 24, pages 952 - 958
    - PERSIC ET AL., GENE, (1997), vol. 187, pages 9 - 18
    - BURTON ET AL., ADVANCES IN IMMUNOLOGY, (1994), vol. 57, pages 191 - 280
    - ALTSCHUL, S.F. ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
    - GISH, W.; STATES, D.J., NATURE GENET., (1993), vol. 3, pages 266 - 272
    - MADDEN, T.L. ET AL., METH. ENZYMOL., (1996), vol. 266, pages 131 - 141
    - ALTSCHUL, S.F. ET AL., NUCLEIC ACIDS RES., (1997), vol. 25, pages 3389 - 3402
    - ZHANG, J.; MADDEN, T.L., GENOME RES., (1997), vol. 7, pages 649 - 656
    - VAUGHAN, NATURE BIOTECHNOLOGY, (1998), vol. 16, pages 535 - 539
    - RAVETCH, JV. ET AL., CELL, (1981), vol. 27, pages 583 - 591
    - HIETER, PA. ET AL., J. BIOL. CHEM., (1982), vol. 257, pages 1516 - 1522
    - REICHMANN ET AL., NATURE, (1998), vol. 332, pages 323 - 324
    - HOLLIGER; HUDSON, NATURE BIOTECH., (2005), vol. 23, no. 9, pages 1126 - 1136
    - ADAIR; LAWSON, DRUG DESIGN REVIEWS - ONLINE, (2005), vol. 2, no. 3, pages 209 - 217
    - VERMA ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, (1998), vol. 216, pages 165 - 181
    - ANGAL ET AL., MOLECULAR IMMUNOLOGY, (1993), vol. 30, no. 1, pages 105 - 108
    - HARRIS, RJ., JOURNAL OF CHROMATOGRAPHY, (1995), vol. 705, pages 129 - 134
    - ERICSSON, ANALYTICAL BIOCHEMISTRY, (2006), vol. 357, pages 289 - 298
    - YANG ET AL., J. MOL. BIOL., (1995), vol. 254, pages 392 - 403
    - MARKS ET AL., BIO/TECHNOLOGY, (1992), vol. 10, pages 779 - 783
    - LOW ET AL., J. MOL. BIOL., (1996), vol. 250, pages 359 - 368
    - PATTEN ET AL., CURR. OPIN. BIOTECHNOL., (1997), vol. 8, pages 724 - 733
    - THOMPSON ET AL., J. MOL. BIOL., (1996), vol. 256, pages 77 - 88
    - CRAMERI ET AL., NATURE, (1998), vol. 391, pages 288 - 291
    - THORPE ET AL., IMMUNOL. REV., (1982), vol. 62, pages 119 - 58
    - DUBOWCHIK ET AL., PHARMACOLOGY AND THERAPEUTICS, (1999), vol. 83, pages 67 - 123
    - CHAPMAN, ADVANCED DRUG DELIVERY REVIEWS, (2002), vol. 54, pages 531 - 545
    - CHAPMAN, A., ADVANCED DRUG DELIVERY REVIEWS, (2002), vol. 54, pages 531 - 545
    - ANGAL ET AL., MOL IMMUNOL., (1993), vol. 30, no. 1, pages 105 - 8
    - BEBBINGTON ET AL., BIOTECHNOL., (1992), vol. 10, no. 2, pages 169 - 175
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.